Philanthropy Asia Alliance Launches Two New Communities to Tackle Health Challenges and Accelerate Asia's Just Energy Transition
SINGAPORE - Media OutReach Newswire - 5 May 2025 - The Philanthropy Asia Alliance (PAA) today announced the launch of two new Communities – the Health for Human Potential (HHP) Community and the Just Energy Transition (JET) Community – at the Philanthropy Asia Summit 2025. These Communities build on PAA's ongoing efforts to convene stakeholders around shared challenges and to explore promising pathways for philanthropic collaboration, applying a systems lens to drive scalable solutions in energy, health, and education.
Each Community is helmed by Community Leads – PAA members – who will actively shape, fund and advance each Community's work together with PAA. The Community Leads for each Community are listed in the next two sections.
Developed with PAA members and launched in 2024, the Communities initiative brings together funders, practitioners, and ecosystem partners to collaborate on shared missions and collectively fund high-impact, PAA-evaluated projects. The first three Communities introduced at last year's Summit were Blue Oceans, Sustainable Land Use, and Holistic & Inclusive Education. Since their launch, the first three Communities have forged various pathways, from peer learning and exchange of expertise to piloting collaborative projects.
'The Communities initiative was born from a simple idea: that we can do more, and do better, when we act together,' said Mr Shaun Seow, Chief Executive Officer, Philanthropy Asia Alliance. 'Tackling complex challenges across health, energy, or education calls for differentiated approaches. To drive deep impact, it is critical for PAA to provide focused platforms for collaboration, apart from industry convenings such as the Philanthropy Asia Summit. The two new Communities are another step forward in that direction. We are grateful to all our Community Leads for their commitment, partnership, and belief in our collective impact.'
Health for Human Potential (HHP) Community: Tackling Asia's Health Challenges with Ambition and Urgency
PAA has launched the HHP Community with two objectives: to reduce preventable deaths and disease burdens across Southeast Asia, focusing on maternal, newborn, and child health and nutrition (MNCHN), as well as to tackle infectious diseases. The initial leads of the Health for HHP Community are the Gates Foundation, Institute of Philanthropy, Quantedge Advancement Initiative, Tanoto Foundation, and Temasek Foundation.
Together, they are catalysing a bold ambition to drive lasting improvements in health across Asia. To kickstart efforts, the HHP Community Leads and the Philanthropy Asia Alliance will commit catalytic funding towards a portfolio of projects. With an initial funding target of US$100 million by 2030, the Community aims not only to deliver impact but also to strengthen the broader giving ecosystem by welcoming new partners and building a sustained, long-term coalition committed to improving health outcomes in the region. Discussions with other partners are ongoing and more are expected to join in coming months.
The HHP Community will drive impact across the health innovation and delivery continuum by advancing affordable health solutions, strengthening health systems, promoting cross-sector collaboration, and integrating digital and AI tools into solutions that align with national health priorities. Efforts will initially focus on Indonesia, the Philippines, and Vietnam – Southeast Asia's most populous countries – where important gains have been made but further progress is needed to achieve Sustainable Development Goals related to MNCHN and infectious diseases, including tuberculosis and malaria.
Just Energy Transition Community: Catalysing Philanthropic Action for a Clean and Inclusive Energy Future
Co-led with members including Tara Climate Foundation, Bloomberg Philanthropies, and other philanthropic organisations, PAA has also launched the Just Energy Transition (JET) Community to galvanise philanthropic leadership and accelerate Asia's shift towards clean, inclusive, and people-centred energy solutions. Despite being home to over half the world's population and accounting for more than 50% of global energy consumption[1], Asia receives disproportionately lower philanthropic support for its critical energy transition. Between 2019 and 2023, just 20% of philanthropic funding reached Asia, Africa, and Latin America combined, while nearly 60% flowed to the U.S. and Europe[2].
The JET Community seeks to close this gap, serving as a collaboration platform for philanthropic organisations to support clean energy initiatives that protect the environment, improve livelihoods, and support a better future for millions across the region. It will create space for funders, governments, industry, and local communities to work together and share ideas, build meaningful partnerships, and co-develop initiatives around job creation, workforce reskilling, better health outcomes, and stronger, more resilient communities.
Refer to the Appendix for quotes from the HHP and JET Community Leads.
Scaling Collective Impact: A Systems Approach
At the Philanthropy Asia Summit 2025, both Communities will host kick-off sessions to engage like-minded partners and catalyse collaboration around shared goals. These sessions will mark the start of co-developing each Community's Collective Impact Framework – a strategic blueprint that defines a common mission, scopes the challenge, and sets clear metrics and timelines for progress.
The Communities will also bring together researchers, industry groups, thought leaders, and programme experts — including Temasek Foundation, which brings 18 years of experience piloting and catalysing innovative solutions and programmes with partners in Asia and beyond. Temasek Trust will support the Communities in applying a systems thinking approach to impact design and measurement.
[1] Source: World Economic Forum
[2] Source: ClimateWorks Funding Trends 2024 Report
APPENDIX
Quote Sheet
The issuer is solely responsible for the content of this announcement.
About Philanthropy Asia Alliance
Philanthropy Asia Alliance (PAA) is a Temasek Trust initiative dedicated to catalysing collaborative philanthropy in Asia through dynamic multi-sector partnerships. By harnessing collective strengths, PAA multiplies impact, accelerates positive change, and takes urgent action to address the pressing environmental and social challenges of our time. PAA's flagship programme is the annual Philanthropy Asia Summit. For more information, visit http://philanthropyasiaalliance.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
5 days ago
- Forbes
This Cancer Survivor, Now Biotech CEO, Is In A Race To Help Others Live Longer
Maky Zanganeh was born in Tehran in 1970, nine years before the Islamic Revolution convulsed Iran. She remembers one night in particular, when the military police tear-gassed a house at the end of the cul-de-sac next to where her family lived and sprayed it with machine gun fire. She and her two older sisters were home alone. 'In the morning, we woke up at 7 o'clock and had to go to school as if nothing happened,' she says matter-of-factly. 'That was my life when I was in Iran.' Mauricio Candela for Forbes That preternatural composure and no-nonsense attitude has helped Zanganeh navigate a life filled with more twists and turns than a Persian bazaar. A couple years after that horrific night in Tehran, Zanganeh's parents, both architects, fled Iran for Germany. She got a degree in dentistry, then an MBA, but ended up working for an American medical robotics outfit, where she met Bob Duggan, a prominent Scientologist, serial entrepreneur and eventual billionaire with whom she would have a son and later marry. She earned hundreds of millions as an investor and executive, speaks four languages (Farsi, German, English, French), survived breast cancer and runs, as co-CEO with Duggan, Miami-based Summit Therapeutics, a Nasdaq-listed biotech that has minted her a $1.5 billion fortune of her own. That wealth has landed Zanganeh, now 54, on Forbes' list of America's Richest Self-Made Women (at No. 23) for the first time. She is one of 38 self-made female U.S. billionaires on the list, and one of just five to have made a billion-dollar-plus fortune in health care. When she and Duggan took over Summit in 2020, the company had less than $1 million in revenue, tens of millions in losses and just one promising drug in its pipeline, an antibiotic that was shelved in 2022. In less than five years, Zanganeh and Duggan—who married in December—have become biotech stars. Key to their success: licensing an overlooked cancer drug candidate from a company in China. That drug, ivonescimab, now seems likely to be a blockbuster. In a clinical trial last year, it outperformed Keytruda, the world's best-selling drug, which generated nearly $30 billion in 2024 sales for Merck. Investors have driven up Summit shares 575% over the past 12 months, giving it a recent market capitalization of nearly $21 billion, despite having no revenue. 'I think of her as probably the most underrated executive in all of biotech,' says Ken Clark, a partner at law firm Wilson Sonsini Goodrich & Rosati, who for more than three decades has worked with hundreds of biotech companies and served on multiple boards—including that of Summit Therapeutics. According to Clark, Zanganeh stands out because of how she and Duggan, neither of whom comes from a traditional biotech background, work together to question established wisdom and get things done quickly in unconventional ways. Ivonescimab is now in multiple Phase III trials for different forms of lung cancer, and Summit plans to submit an application for FDA approval by the end of the year. It can't come too soon. Even after advances in treatment and detection of lung cancer over the past two decades, 125,000 Americans die from the disease each year—more than twice the number of deaths from any other cancer, per the National Cancer Institute. What's novel about Summit's drug is how it goes after the cancer in two ways. It stimulates the immune system to attack the cancer cells while also starving the cancer by cutting off blood supply to the tumors. Based on the clinical trial in China last year, the two-pronged approach works. Those on Summit's drug went a median 11.1 months before the cancer returned, compared to 5.8 months for those taking Keytruda. The results, announced last September, led Summit's stock to more than double in four days. Zanganeh's journey from schoolgirl in Tehran to Miami biotech CEO took an unusual route. In 1984, five years after the Shah of Iran was overthrown, her parents moved with her to Germany. Zanganeh settled down with an uncle in Oldenburg, a small city about 30 miles from Bremen, while her parents continued to shuttle between Europe and Iran. Old-fashioned values prevailed: good manners, good health and lots of studying. 'Education was a top priority,' Zanganeh says. Her older sisters both went to medical school in Strasbourg, France. She chose to study dentistry instead and graduated from Louis Pasteur University (now the University of Strasbourg) in 1995. She soon realized dentistry was not for her. 'It was like being in a box every day, doing the same thing,' she says. In 1997, a friend of her sister's told Zanganeh about her job at a U.S. company called Computer Motion, which manufactured robotic arms used to perform minimally invasive surgery. Zanganeh was fascinated and landed a job in the Strasbourg office. Her father convinced her that if she was going to go into business, she would need an MBA, so studying part-time she earned one from Schiller International University in 1998. At 28, Zanganeh was promoted to oversee Computer Motion's business in Europe and the Middle East, which involved visiting surgeons in Dubai, Saudi Arabia and Egypt, introducing them to what was then a new technology. That's also when Zanganeh began working with Computer Motion's CEO, Bob Duggan, who had invested in the company back in 1989. Duggan, now 81, was the yin to Zanganeh's yang. She had been a diligent student and dedicated employee who earned an advanced degree. He had spent at least five years at UC Santa Barbara and UCLA without earning a degree, was a passionate surfer and had worked for himself, except for a brief three-year stint, since he started mowing lawns as a teenager. He's an idea guy with an analytical mind who thinks and talks fast, while Zanganeh excels at process and execution. 'We're very simpatico,' Duggan says. 'She knows all the details and she's got a photographic memory. I'm a visionary. I can see around corners.' In 2003, after Duggan sold Computer Motion to Intuitive Surgical, they began looking for the next big thing. Zaganeh, who was then working for Duggan's personal investment firm, became intrigued with cancer drug developer Pharmacyclics, a money-losing public company with a potentially promising drug—she says she picked it from a list of 15 companies that came in via fax from an analyst. One of Duggan's sons had died of brain cancer, so the company's purpose resonated. Both Duggan and Zanganeh invested in Pharmacyclics in April 2004; Zanganeh sold her Intuitive Surgical shares and borrowed from the bank to come up with the cash. By 2008 Duggan had increased his stake to the point where he controlled the Sunnyvale, California–based company and installed himself as CEO. Zanganeh also joined, first as vice president of business development and later as chief operating officer. In 2011, armed with a fresh early-stage cancer drug (the first one failed), Duggan began talking up a partnership with Johnson & Johnson, which needed to boost its cancer drug pipeline. Zanganeh made it come to fruition. 'She's a force of nature. She is so thoughtful, so prepared, so data-driven, and then she takes that and makes things happen,' says Michael Gaito, global chairman of investment banking and health care at JPMorgan, whose firm advised Pharmacyclics in when it was sold to AbbieVie in 2015. Zanganeh negotiated a worldwide partnership with J&J that allowed the smaller Pharmacyclics to book the U.S. revenue from the new cancer drug, rather than the typical arrangement in which it would go to the big pharma partner. She also negotiated upfront payments over two years of $400 million. 'The terms of it were revolutionary at the time,' Gaito says. Adds Summit board member Clark: 'She really drove it.' Pharmacyclics' drug, Imbruvica, ended up being a blockbuster treatment for chronic lymphocytic leukemia, one of the most common forms of leukemia in adults. It is far less toxic than the chemotherapy that was the previous standard treatment. A surge in Pharmacyclics' stock price first landed Duggan on Forbes' Billionaires list in 2013, the year Imbruvica got FDA approval. Two years later, drug giant AbbVie bought the company for $21 billion. Zanganeh, who had invested about $1 million in the company, walked away with $225 million before taxes. The cash was especially welcome since it enabled Zanganeh, who had been raising her son, Shaun, on her own, to spend more time being a mom. Back in 2006, when he was born, Zanganeh was traveling so much for work, researching investments with Duggan, that her mother, who lived in France, raised Shaun until he was 5, with Zanganeh flying to France every two weeks to visit. (Duggan recently acknowledged that Shaun is his son.) In 2019, Zanganeh was on a trip to France to visit her father, who was having surgery to remove a cancerous tumor, when she found a lump that turned out to be Stage 2 breast cancer. She had surgery at the same hospital as her dad, then flew home to the U.S., where she started chemotherapy two weeks before Covid-19 lockdowns began in March 2020. It didn't go smoothly: Her heart and lungs practically shut down and she had to be hospitalized. She had bone pain and chronic vomiting. 'I was really, really sick,' she says. 'All of the time, you have this fear. What if it metastasizes?' She says the silver lining was that she got to experience the same challenges as many of the patients her industry exists to serve. During this time, Duggan targeted another struggling biotech. He spent $63 million buying 60% of Summit Therapeutics' shares and became CEO in April 2020. Seven months later, chemo treatments behind her, Zanganeh joined as chief operating officer and board member. In July 2022, she was appointed co-CEO. After initial plans to develop a new antibiotic sputtered, the pair hired a handful of former Pharmacyclics employees and sent them on a quest to find a new cancer drug—anywhere in the world. Fong Clow, a Pharmacyclics veteran originally from China, suggested looking in her home country. In mid-2022 the Summit team zeroed in on ivonescimab, which was made by a Hong Kong–listed firm called Akeso and already in Phase III trials. At the time, there was some hesitation in the industry about partnering with a Chinese drugmaker. In March 2022, the FDA declined to approve a lung cancer drug that Eli Lilly had licensed from China's Innovent Biologics. That's one possible reason Akeso, which had presented some promising research at ASCO, the big annual oncology conference that year, didn't attract big pharma. It wasn't a problem for Zanganeh and Duggan. 'They're just not bound by conventional thinking,' says board member Clark. They were, however, bound by Summit's finances. In September 2022 the company had just over $120 million of cash on hand and a market cap of about $200 million. But Michelle Xia, the founder and CEO of Akeso—who had worked for Bayer and other pharmaceutical companies in the U.S. after getting a Ph.D. in molecular biology in the U.K.—bonded with Zanganeh and Duggan. The two teams quickly discovered they had similar entrepreneurial cultures. 'They found me, and I think it's a perfect fit,' Xia says. In December 2022 the two companies agreed to license Akeso's drug for $500 million upfront (Summit had to borrow from Duggan and Zanganeh to cover the sum) and $4.5 billion in potential milestone payments if ivonescimab gets approved. Zanganeh is optimistic on that front. Ivonescimab is undergoing 11 Phase III trials around the world. Results so far have been mostly positive, though on May 30 the company reported that it missed one of two primary targets–for overall survival–in one of the trials, sending Summit shares plummeting 30% that day. In a June 1 note, Cantor Fitzgerald biotech analyst Eric Schmidt wrote, 'We think the markets got it wrong,' explaining that the trial showed very positive results for the other target, time without disease progression–and that this particular trial is for a small subset of lung cancer patients. As a cancer survivor, Zanganeh knows there is no time to waste. 'The speed of [our] decision making is fast,' she says. 'You want to make sure that you can really help all these patients.' Disclosure: Maky Zanganeh, Summit Therapeutics' co-CEO, published a book in February with Forbes Books, a licensed partner of Forbes.
Yahoo
6 days ago
- Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Summit Therapeutics stock fell hard recently in response to disappointing clinical trial results. Ivonescimab failed to produced a statistically significant overall survival benefit in the phase 3 Harmoni trial. Ivonescimab has been approved by Chinese regulators, but Summit Therapeutics has a license to sell it outside of China. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. Stock markets have a tendency to sell first and ask questions later. After watching this stock plummet, some bargain-shoppers are wondering if it fell too far. Recent trial results missed the mark the company was hoping for, but the results weren't entirely discouraging. Let's weigh the bad news against the good to see if this stock could be a beaten-down bargain. Summit Therapeutics and its investors have been eagerly anticipating results from the phase 3 Harmoni trial of ivonescimab. It's a bispecific antibody that works like a compination of Keytruda (a PD-1 inhibitor) plus Avastin (a VEGF inhibitor). Summit's stock price rocketed higher in 2024 thanks to Harmoni-2 trial results that showed it outperformed Keytruda at limiting tumor growth in lung cancer patients. Although ivonescimab is already approved in China, it's not for sale in the U.S. and EU, where Summit Therapeutics has a license to sell it. The Harmoni trial enrolled second-line lung cancer patients and treated them with ivonescimab or a placebo plus standard chemo. The treatment reduced the risk of disease progression in terms of tumor growth by 48%, but failed to show a convincing overall survival benefit. Adding ivonescimab to standard chemo reduced patients' risk of death by 21%, but the results fell just outside a 95% confidence interval with a p-value of 0.057. It's highly unlikely the Food and Drug Administration will approve ivonescimab for sale in the U.S. based on the Harmoni trial results. According to Summit, the FDA has been clear about the need for a statistically significant overall survival benefit to support an application. The China-based company that owns ivonescimab, Akeso, recently earned a second approval to market the therapy to lung cancer patients in China. Keytruda sales rose to $29.5 billion last year, and a treatment that can outperform the leader could do even better. Ivonescimab is unlikely to earn approval in the U.S. for patients similar to those enrolled in the Harmoni trial. Given its ability to shrink tumors, though, it's probably just a matter of time before it produces statistically significant overall survival results for an underserved patient population. Tumor responses get attention, but oncologists are far more interested in giving patients a chance for long-term survival. Keytruda's a top seller now because it produced dramatic overall survival results, compared to the standard treatments of its time. The lack of convincing overall survival data so far for ivonescimab severely reduces the odds that it will go on to produce blockbuster sales in the places where Summit Therapeutics has a license to sell it. Despite the obvious challenges ahead, expectations are still sky-high. Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is the only candidate in its pipeline. Despite the lack of options and an uncertain path forward, the stock finished May with a market cap above $13.5 billion. If ivonescimab goes on to produce sales anywhere near Keytruda's, investors who bought Summit Therapeutics at recent prices could reap enormous gains. Unfortunately, the Harmoni trial's failure to produce a convincing overall survival benefit suggests that future sales will be muted, even if the company can get it past the FDA. It's probably best to watch this story play out from a safe distance. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? was originally published by The Motley Fool Sign in to access your portfolio
Fox News
30-05-2025
- Fox News
Fox News' Mike Tobin completes risky Everest climb and shares details of high-stakes summit
Fox News Senior Correspondent Mike Tobin has completed one of the riskiest feats in the world: climbing Mount Everest. Along with a team, Tobin hiked the mountain in the Himalayas, reaching the highest point on Earth. Tobin was back on the channel, joining "America's Newsroom" on Friday from China to share the details of his experience. "Some people say weather-wise, it was one of the best summit windows they've seen in like 20 years," said Tobin. "And you compare that to the other people who climbed this Everest season, most of them got beat up on the summit." He said that his team saw people going down the mountain with "big black mittens on," indicating that "they were covering up frostbite damage." Tobin shared that when he reached the summit, it was a little bit cloudy. "I'm very well aware that 90% of the accidents happen on the way down and so you're tired, you're a little hypoxic, and it was a moment of concentration for me," said Tobin. "I wanted to make sure that I didn't let up because we still had a long way to get down to advanced base camp." In 2023, 12 climbers were reported dead while five went missing following 478 hiking permits issued by Nepal, according to Reuters. "I was just trying to think, 'Keep your head about yourself. Don't make any mistakes, don't turn what's otherwise going to be a celebration into a tragedy.'" About 700 to 1,000 climbers attempt the summit each year, with success rates ranging between 60% and 70%, according to Climbing Kilimanjaro. "Keep your head about yourself. Don't make any mistakes." Tobin said that he "certainly was spooked at different times on the climb," sharing that it hit him when he came back down on the second step. The second step is on the northeast ridge of Mount Everest, one of three major obstacles. He said it was a bit "odd" as he "was pretty enthused on the way up," but added other team members shared that the moment was spooky for them, too. While in the "death zone," Tobin participated in the 22 Pushup Challenge to raise awareness about the issue of veteran and first responder suicide. "The only way you survive the death zone is to get in and out of there as fast as you can before the sand runs out of your hourglass or before the oxygen runs out of your bottle," said Tobin. The "death zone" is an area above 26,247 ft. on the mountain; the air is too thin to support human life without supplemental oxygen. "It was kind of an add-on to the climb … You've seen some of the different events that people have done as far as the 22 push-ups in recognition of veteran suicide," said Tobin. "I hope that a troubled guy out there somewhere who was looking at suicide as a reasonable response to his troubles will realize that someone took the time to do that in a perilous situation and reconsider before he hurts himself," he added. Tobin credited his wife for keeping him on track during his preparation leading up to the hike. "Between work and training for Everest, there really wasn't any time, and she ran the house and made sure I got fed." He shared that the training process was pretty arduous. "I did crazy kinds of training, like I'd take the sandbags that our cameramen use, and I put them in a backpack, and I ran up and down the Indiana Sand Dunes for hours at a time," said Tobin.
